Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

2.0K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
2.0K
Regulated Protein Degradation02:58

Regulated Protein Degradation

6.6K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
6.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Bioactivation and Tissue Toxicity01:25

Bioactivation and Tissue Toxicity

151
Bioactivation is a metabolic process that transforms less reactive substances into highly reactive metabolites, initiating tissue toxicity. This transformation can lead to various toxic effects, including carcinogenesis and teratogenesis. Reactive metabolites are classified into two main types: electrophiles and free radicals.Electrophiles are electron-deficient species and are produced primarily by the enzyme cytochrome P-450 during the metabolism of compounds containing carbon, nitrogen, or...
151
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

8.2K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
8.2K
The Proteasome01:13

The Proteasome

1.6K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

New Modalities and Carcinogenicity Assessment.

Toxicologic pathology·2026
Same author

Transmission Electron Microscopy of the Peripheral Nervous System: Methods, Sample Preparation, and Case Studies.

Toxicologic pathology·2025
Same author

International Harmonization of Nomenclature and Diagnostic Criteria (INHAND): Nonproliferative and Proliferative Lesions of Nonrodent Ocular Tissues.

Toxicologic pathology·2024
Same author

Neurofilament Light Chain: A Translational Safety Biomarker for Drug-Induced Peripheral Neurotoxicity.

Toxicologic pathology·2023
Same author

Intrathecal sc-AAV9-CB-GFP: Systemic Distribution Predominates Following Single-Dose Administration in Cynomolgus Macaques.

Toxicologic pathology·2022
Same author

International Harmonization of Nomenclature and Diagnostic Criteria (INHAND): Nonproliferative and Proliferative Lesions of the Dog.

Toxicologic pathology·2021

Related Experiment Video

Updated: Apr 30, 2026

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

11.7K

Carcinogenicity Risk Assessment of Targeted Protein Degraders.

James Sidaway1, Emily E Meseck2

  • 1ApconiX, Alderley Edge, UK.

Toxicologic Pathology
|April 29, 2026
PubMed
Summary

Targeted protein degraders (TPDs) require careful carcinogenicity risk assessment. Novel weight-of-evidence approaches and E3 ligase evaluation are crucial for drug development safety.

Keywords:
carcinogenicity assessmentcereblonmolecular glue degradernonclinical safetytargeted protein degrader

More Related Videos

Assays for the Degradation of Misfolded Proteins in Cells
10:56

Assays for the Degradation of Misfolded Proteins in Cells

Published on: August 28, 2016

11.7K
Reporter-based Growth Assay for Systematic Analysis of Protein Degradation
07:47

Reporter-based Growth Assay for Systematic Analysis of Protein Degradation

Published on: November 6, 2014

10.3K

Related Experiment Videos

Last Updated: Apr 30, 2026

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

11.7K
Assays for the Degradation of Misfolded Proteins in Cells
10:56

Assays for the Degradation of Misfolded Proteins in Cells

Published on: August 28, 2016

11.7K
Reporter-based Growth Assay for Systematic Analysis of Protein Degradation
07:47

Reporter-based Growth Assay for Systematic Analysis of Protein Degradation

Published on: November 6, 2014

10.3K

Area of Science:

  • Pharmacology
  • Toxicology
  • Drug Discovery

Background:

  • Targeted protein degraders (TPDs) represent a new therapeutic modality engaging E3 ubiquitin ligase complexes for protein degradation.
  • Molecular glue degraders (MGDs) and proteolysis-targeting chimeras (PROTACs) are key TPD types, with several cereblon-based agents in clinical trials for oncology.
  • Carcinogenicity risk assessment is essential for TPDs, even for non-life-threatening indications.

Purpose of the Study:

  • To explore modified weight-of-evidence (WoE) approaches for carcinogenicity risk assessment of TPDs.
  • To highlight the importance of evaluating E3 ligase biology alongside the primary target in toxicology assessments.
  • To address challenges in interpreting data from early-generation cereblon MGDs.

Main Methods:

  • Review of TPD properties influencing carcinogenicity assessment.
  • Presentation of case studies illustrating evolved WoE approaches.
  • Emphasis on biological assessment of E3 ligases and primary targets.

Main Results:

  • TPD properties necessitate tailored carcinogenicity risk assessment strategies.
  • Modified WoE approaches, incorporating E3 ligase biology, may be acceptable to regulatory agencies.
  • Early-generation cereblon MGDs present unique challenges for data interpretation and translatability.

Conclusions:

  • Evolved carcinogenicity risk assessment strategies are needed for TPDs.
  • Comprehensive evaluation of E3 ligase function is critical for TPD safety assessment.
  • Drug developers must navigate specific limitations associated with early TPDs to ensure reliable safety profiles.